Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 2

Lubiprostone: a novel treatment for chronic constipation

Authors Brian E Lacy, L Campbell Levy

Published Date June 2008 Volume 2008:3(2) Pages 357—364

DOI http://dx.doi.org/10.2147/CIA.S2938

Published 30 June 2008

Brian E Lacy, L Campbell Levy

Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon NH, USA

Abstract: Chronic constipation is highly prevalent, reduces patients’ quality of life, and imposes a significant health care burden on society. Lifestyle modifications and over-the-counter agents improve symptoms of constipation in some patients, however many patients have persistent symptoms and require the use of prescription medications. Three prescription medications are currently Food and Drug Administration (FDA) approved and available for the treatment of chronic constipation in adults. This review will focus on lubiprostone, the newest medication available for the treatment of chronic constipation. Lubiprostone is a bicyclic fatty acid metabolite analogue of prostaglandin E1. It activates specific chloride channels in the gastrointestinal tract to stimulate intestinal fluid secretion, increase gastrointestinal transit, and improve symptoms of constipation. This article will provide a brief overview on chloride channel function in the gastrointestinal tract, describe the structure, function, and pharmacokinetics of lubiprostone, and discuss the safety and efficacy of this new medication.

Keywords: chloride, chloride channels, constipation, functional bowel disorders, gastrointestinal motility, intestinal secretion, irritable bowel syndrome, lubiprostone

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Epidemiological and mortality analysis of older adults with HIV in eastern China

Xie TS, Wu NP

Clinical Interventions in Aging 2013, 8:1519-1525

Published Date: 19 November 2013

Gold nanoparticles as physiological markers of urine internalization into urothelial cells in vivo

Hudoklin S, Zupančič D, Makovec D, Kreft ME, Romih R

International Journal of Nanomedicine 2013, 8:3945-3953

Published Date: 14 October 2013

Outcome mapping for health system integration

Tsasis P, Evans JM, Forrest D, Jones RK

Journal of Multidisciplinary Healthcare 2013, 6:99-107

Published Date: 14 March 2013

Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease

Mannu P, Rinaldi S, Fontani V, Castagna A

Clinical Interventions in Aging 2011, 6:207-211

Published Date: 26 July 2011

Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor

Mannu P, Rinaldi S, Fontani V, Castagna A

Neuropsychiatric Disease and Treatment 2011, 7:373-379

Published Date: 15 June 2011

The benefits and risks of testosterone replacement therapy: a review

Nazem Bassil, Saad Alkaade, John E Morley

Therapeutics and Clinical Risk Management 2009, 5:427-448

Published Date: 11 June 2009

Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite

Takahiro Ueno, Hironori Tsuchiya, Maki Mizogami, Ko Takakura

Journal of Inflammation Research 2008, 1:41-48

Published Date: 13 November 2008